Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akio Asai

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumorsKeisuke Ueki, Ryo Nishikawa, Yoichi Nakazato, et al.
Neuro-Oncology|October 26, 2021
12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumorsKaishi Satomi, Hirokazu Takami, Shintaro Fukushima, et al.
Scientific Reports|September 21, 2023
Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumorsHirokazu Takami, Kaishi Satomi, Kohei Fukuoka, et al.
Neuro-Oncology|August 18, 2019
Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT ConsortiumHirokazu Takami, Kohei Fukuoka, Shintaro Fukushima, et al.
Cancer Cell|February 10, 2016
Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent MannerSung-Hak Kim, Ravesanker Ezhilarasan, Emma Phillips, et al.
Neuro-Oncology|November 5, 2022
Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114CKazuhiko Mishima, Ryo Nishikawa, Yoshitaka Narita, et al.
Neuro-Oncology Advances|September 22, 2021
Low tumor cell content predicts favorable prognosis in germinoma patientsHirokazu Takami, Kaishi Satomi, Kohei Fukuoka, et al.
Neuro-Oncology|February 9, 2022
Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterpartsHirokazu Takami, Asmaa Elzawahry, Yasin Mamatjan, et al.
Neuro-Oncology|November 4, 2024
Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up studyHirokazu Takami, Masao Matsutani, Tomonari Suzuki, et al.
Cancer Chemotherapy and Pharmacology|December 12, 2012
Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)Soichiro Shibui, Yoshitaka Narita, Junki Mizusawa, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumorsKeisuke Ueki, Ryo Nishikawa, Yoichi Nakazato, et al.
Neuro-Oncology|October 26, 2021
12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumorsKaishi Satomi, Hirokazu Takami, Shintaro Fukushima, et al.
Scientific Reports|September 21, 2023
Distinct patterns of copy number alterations may predict poor outcome in central nervous system germ cell tumorsHirokazu Takami, Kaishi Satomi, Kohei Fukuoka, et al.
Neuro-Oncology|August 18, 2019
Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT ConsortiumHirokazu Takami, Kohei Fukuoka, Shintaro Fukushima, et al.
Cancer Cell|February 10, 2016
Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent MannerSung-Hak Kim, Ravesanker Ezhilarasan, Emma Phillips, et al.
Neuro-Oncology|November 5, 2022
Randomized phase III study of high-dose methotrexate and whole-brain radiotherapy with/without temozolomide for newly diagnosed primary CNS lymphoma: JCOG1114CKazuhiko Mishima, Ryo Nishikawa, Yoshitaka Narita, et al.
Neuro-Oncology Advances|September 22, 2021
Low tumor cell content predicts favorable prognosis in germinoma patientsHirokazu Takami, Kaishi Satomi, Kohei Fukuoka, et al.
Neuro-Oncology|February 9, 2022
Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterpartsHirokazu Takami, Asmaa Elzawahry, Yasin Mamatjan, et al.
Neuro-Oncology|November 4, 2024
Phase II trial of pathology-based tripartite treatment stratification for patients with CNS germ cell tumors: A long-term follow-up studyHirokazu Takami, Masao Matsutani, Tomonari Suzuki, et al.
Cancer Chemotherapy and Pharmacology|December 12, 2012
Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305)Soichiro Shibui, Yoshitaka Narita, Junki Mizusawa, et al.
Pageof 7